Treatment package time in high-risk oral cavity squamous cell carcinoma: Where are we failing and at what cost?
Abstract
Background: The gold-standard of treatment for oral cavity squamous cell carcinoma (OCSCC) is surgery and adjuvant chemoradiotherapy (CRT) in the sub-group of high-risk patients. In this group of patients, treatment time is an important factor in clinical outcomes. We aim to study the influence of the treatment package time (TPT).
Materials and methods: We conducted a retrospective study of patients with high-risk OCSCC managed with surgery followed by adjuvant CRT between January 2017 and December 2020. TPT was defined as the time between surgery and the last fraction of radiotherapy. We categorized TPT according to an optimal cut-off point. The Kaplan-Meier methodology was used to calculate 5-year survival.
Results: We included 79 patients, median age: 60 years (range: 39–70 years), majority were male (84.8%, n = 67) and smokers (73.4%, n = 58). Extra-nodal extension (ENE) and positive resection/< 1 mm margin were found in 51.9% (n = 41) and 84.8% (n = 67) of cases, respectively. Median radiotherapy dose: 66 Gy. Median cisplatin dose: 300 mg/m2. Median TPT time was 109 days. The optimal cut-off point was 104 days. 5-year overall survival (OS) with TPT ≤ 104 days was 77.4% and 46.7% with TPT > 104 days, with similar results for disease-free survival (DFS).
Conclusions: Our institution cohort of high risk OCSSC treated with surgery followed by adjuvant CRT had a prolonged TPT (median 109 days). Within our cohort, a TPT > 104 days was found to have a worse OS and DFS, with a nonsignificant impact on locoregional or distant disease-free survival. This highlights the need to optimize the multimodal cancer care pathway.
Keywords: oral cavityadjuvant chemoradiotherapytreatment package time
References
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- World Health Organization. Portugal — Global Cancer Observatory. Globocan 2020; 501: 1–2. https://gco.iarc.fr/today/data/factsheets/populations/620-portugal-fact-sheets.pdf.
- National Comprehensive Cancer Network. NCCN clinical Practice Guidelines in Oncology: Head and neck Cancer Version 1.2023. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
- Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27(10): 843–850.
- Bernier J, Domenge C, Ozsahin M, et al. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350(19): 1945–1952.
- Cooper JS, Zhang Q, Pajak TF. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012; 84(5): 1198–1205.
- Machiels JP, René Leemans C, Golusinski W, et al. EHNS Executive Board. Electronic address: secretariat@ehns.org, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, ESTRO Executive Board. Electronic address: info@estro.org. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(11): 1462–1475.
- Huang J, Barbera L, Brouwers M, et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003; 21(3): 555–563.
- Mazul AL, Stepan KO, Barrett TF, et al. Duration of radiation therapy is associated with worse survival in head and neck cancer. Oral Oncol. 2020; 108: 104819.
- Rosenthal DI, Mohamed ASR, Garden AS, et al. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2017; 98(5): 1002–1011.
- Graboyes EM, Garrett-Mayer E, Ellis MA, et al. Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer. Cancer. 2017; 123(24): 4841–4850.
- Guttmann DM, Kobie J, Grover S, et al. National disparities in treatment package time for resected locally advanced head and neck cancer and impact on overall survival. Head Neck. 2018; 40(6): 1147–1155.
- Tam M, Wu SP, Gerber NK, et al. The impact of adjuvant chemoradiotherapy timing on survival of head and neck cancers. Laryngoscope. 2018; 128(10): 2326–2332.
- Morse E, Berson E, Fujiwara R, et al. Treatment delays in oral cavity squamous cell carcinoma and association with survival. Head Neck. 2017; 39(4): 639–646.
- Chen MM, Harris JP, Orosco RK, et al. Association of Time between Surgery and Adjuvant Therapy with Survival in Oral Cavity Cancer. Otolaryngol Head Neck Surg. 2018; 158(6): 1051–1056.
- I Ghanem A, Woody NM, Schymick MA, et al. Influence of Treatment Package Time on outcomes in High-Risk Oral Cavity Carcinoma in patients receiving Adjuvant Radiation and Concurrent Systemic Therapy: A Multi-Institutional Oral Cavity Collaborative study. Oral Oncol. 2022; 126: 105781.